Full-Time

Scientist – Oligonucleotide Chemistry

Confirmed live in the last 24 hours

Korro Bio

Korro Bio

51-200 employees

Develops RNA-based therapies for diseases

Biotechnology
Healthcare

Senior

Cambridge, MA, USA

Position is onsite in Cambridge, MA.

Category
Bioinformatics
Computational Biology
Genomics
Public Health
Biology Lab & Research
Biology & Biotech
Requirements
  • Ph.D. in Chemistry or equivalent discipline with focus on nucleic acid chemistry with 5+ years of relevant experience.
  • Solid understanding of nucleoside/nucleotide/oligonucleotide chemistry and biology with an in-depth understanding of the commonly used modifications in oligonucleotide therapeutics.
  • Deep understanding of RNA structure and its interactions in biological systems, preferably with hands on experience running in vitro assays.
  • Must have hands on experience with the operation of low- and high-throughput oligonucleotide synthesis machinery (Mermade, Dr. Oligo) and routine laboratory instruments such as HPLC/UPLC, UV thermal melting, LCMS.
  • Strong communication skills in a variety of settings, ability to share and discuss scientific data clearly to peers and to senior leadership.
  • Proven track record in the field of oligonucleotide therapeutics (patents, publications, conference presentations, etc).
  • Team oriented and collaborative approach to work across multiple teams.
  • Attention to detail, critical analysis of data/reports, and troubleshooting abilities.
  • Proven ability to achieve results, keep projects on timeline, and find solutions as needed to ensure that project deliverables are met.
Responsibilities
  • Contribute to the development of Korro Bio’s proprietary medicinal chemistry platform.
  • Perform oligonucleotide solid phase synthesis and purification and delivery of high-quality oligonucleotides at low to mid scales for in vitro and in vivo studies.
  • Operate independently in the lab using all standard modern oligonucleotide synthesizers (Mermade, Dr. Oligo), purifiers (HPLC, Akta) and analysis (HPLC, LCMS).
  • Actively keep up to date with the ongoing research in the RNA therapeutics field and contribute to the development of proprietary designs and drafting of the patent applications.
  • Collaborate cross-functionally with Biology, Delivery, and In Vitro and In Vivo Pre-clinical Pharmacology teams to advance Korro Bio’s early research activities to preclinical development.
  • Independently run laboratory experiments to support and advance discovery efforts.
  • Multi-task across several projects and manage time effectively in a fast paces environment to achieve results.
  • Design and write protocols, perform experiments, organize and analyze data, interpret results, record experiments in an electronic lab notebook, and summarize work in presentations and technical reports.
  • Adhere to all laboratory safety requirements and standard operating procedures, help maintaining general laboratory functionality, including lab equipment maintenance and the ordering, and receiving of lab supplies.
  • Other duties as assigned.

Korro Bio develops RNA-based therapies aimed at treating serious diseases that currently lack effective treatments. The company uses RNA editing to make precise modifications at the RNA level, which allows for accurate changes to protein function. This method is seen as more precise and potentially safer than traditional gene editing techniques. Korro Bio focuses on research and development to create new therapies, which it can market independently or through partnerships with larger pharmaceutical companies. The company serves healthcare providers, hospitals, and patients, and collaborates with academic institutions to enhance its research. Korro Bio's goal is to make significant scientific advancements in medicine accessible to patients in need.

Company Stage

IPO

Total Funding

$383.7M

Headquarters

Cambridge, Massachusetts

Founded

2019

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

7%
Simplify Jobs

Simplify's Take

What believers are saying

  • Korro Bio raised $70M for clinical trials and growth in April 2024.
  • Partnership with Novo Nordisk targets cardiometabolic diseases like obesity and diabetes.
  • Recent FDA approval of RNA therapy may accelerate Korro Bio's regulatory pathway.

What critics are saying

  • Potential competition from Beam Therapeutics in RNA editing technologies.
  • Merger with Frequency Therapeutics may lead to integration challenges.
  • Stock price surge could lead to increased scrutiny and volatility.

What makes Korro Bio unique

  • Korro Bio uses RNA editing for precise protein function modifications.
  • Their platform targets diseases with limited or no current treatment options.
  • Korro Bio's RNA editing is considered superior to traditional gene editing.

Help us improve and share your feedback! Did you find this helpful?